Evidence map›Paper›PMID 32257532›Full record

ArticlePrecision clinical medicine2020

Double negative T cells, a potential biomarker for systemic lupus erythematosus.

Jessy J Alexander, Alexander Jacob, Anthony Chang, Richard J Quigg, James N Jarvis

Abstract read
In one paragraph

Article in Precision clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Nonspecific increase of αβTCRWorld journal of pediatrics : WJP · 2024
    Observational
  3. Double-negative T cells in pediatric rheumatic diseases.Clinical and experimental pediatrics · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. T-cell receptor αβImmunology and cell biology · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. CD3Frontiers in immunology · 2022
    Review
  17. T Cells in Systemic Lupus Erythematosus.Rheumatic diseases clinics of North America · 2021
    Review
  18. Article
  19. Frontiers in immunology · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jessy J AlexanderDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.
Alexander JacobDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.
Anthony ChangDepartments of Medicine, Pediatrics, Jacobs School of Medicine and Biomedical Sciences and Genetics, Genomics, & Bioinformatics Program, University at Buffalo, Buffalo, NY 14203, USA.
Richard J QuiggDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.
James N JarvisDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.

Funding

Mechanisms of Complement Dependent Immune Complex-Mediated GlomerulonephritisR01DK111222 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI ALEXANDER, JESSY J · 2018 to 2020
$712k
NIDDK NIH HHS R01 DK111222
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that is a challenge to diagnose and treat. There is an urgent need for biomarkers to help define organ involvement, and more effective therapies. A unique population of T cells, the CD3

Indexed as

CD3+CD4−CD8− T cellsglomerulonephritisinflammationlupus

Identifiers

PMID32257532
PMCPMC7093895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.